D-153 Solution
NDC Package 58264-0164-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

D-153 (juglans regia leaf, lachesis, calcarea carbonica, lycopodium, phosphorus, magnesium phosphate) solution is a medication used as Temporary relief from symptoms associated with pancreas, liver or gall bladder weakness, inefficient insulin production and utilization. This formulation utilizes a solution delivery system. Marketed by Dna Labs, this product is identified by NDC 58264-0164.

Identification & Billing

NDC Package Code
58264-0164-1
Package Description
29.57 mL in 1 BOTTLE, GLASS
Product Code
58264-0164
11-Digit Billing Format
58264016401

Clinical Specifications

Proprietary Name
D-153
Non-Proprietary Name
Juglans Regia Leaf, Lachesis, Calcarea Carbonica, Lycopodium, Phosphorus, Magnesium Phosphate
Substance Name
Juglans Regia Leaf; Lachesis Muta Venom; Lycopodium Clavatum Spore; Magnesium Phosphate, Dibasic Trihydrate; Oyster Shell Calcium Carbonate, Crude; Phosphorus
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Sublingual - Administration beneath the tongue.
Active Ingredient(s)
Pharmacologic Class
Usage Information
This product is used as Temporary relief from symptoms associated with pancreas, liver or gall bladder weakness, inefficient insulin production and utilization.

Regulatory & Marketing

Labeler Name
Dna Labs
Product Type
Human Otc Drug
Marketing Category
UNAPPROVED HOMEOPATHIC - A category specifying that a product is marketed as unapproved homeopathic product.
Start Marketing Date
02-11-2023
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 58264-0164-1 identifies a specific commercial package of 29.57 ml in 1 bottle, glass of D-153, a human over the counter drug labeled by Dna Labs. This solution is formulated for sublingual use and contains juglans regia leaf; lachesis muta venom; lycopodium clavatum spore; magnesium phosphate, dibasic trihydrate; oyster shell calcium carbonate, crude; phosphorus as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dna Labs on February 11, 2023. The current certification is valid through December 31, 2026.

How is this Dna Labs product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 58264016401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
58264-0164-1
11-Digit CMS (5-4-2)
58264-0164-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.